S-1: Aptevo Therapeutics Files for Resale of Shares Issuable Upon Warrant Exercise

Sentiment:

S-1 Filing 13 May 2025 5:30 PM

📋All filings for Aptevo Therapeutics INC

Aptevo Therapeutics is registering for resale up to 3,529,420 shares of common stock issuable upon the exercise of common stock purchase warrants.

Capital raiseAptevo entered into a Purchase Agreement with certain institutional investors.The Holders agreed to purchase 1,764,710 shares of our Common Stock and, in a concurrent private placement, Common Warrants to purchase up to 3,529,420 shares of Common Stock at a combined offering price of $1.19 per share.We received aggregate net proceeds of $1.9 million from the April 2025 Offering after deducting financial advisory fees and other expenses payable by us.We would expect to receive aggregate gross proceeds of up to approximately $4.2 million if the Common Warrants are exercised.

Summary

Aptevo Therapeutics has filed a registration statement for the resale of up to 3,529,420 shares of its common stock.
These shares are issuable upon the exercise of common stock purchase warrants that were issued in a private placement alongside a registered direct offering in April 2025.
The combined purchase price of one share of common stock and an accompanying warrant was $1.19.
The company is registering these shares to satisfy certain registration rights granted to the holders of the warrants.
Aptevo will not receive any proceeds from the sale of these shares by the holders.
As of May 12, 2025, Aptevo had 7,678,395 shares of common stock outstanding.
The last reported sale price of Aptevo's common stock on May 12, 2025, was $0.34 per share.

Sentiment

Score: 5

Explanation: Neutral sentiment. The document primarily concerns the registration for resale of existing securities, with no explicit positive or negative implications for the company's operations. The potential for dilution and the risk of delisting are balanced by the fulfillment of contractual obligations.

Positives

Registration of the resale shares fulfills the company's obligations under the purchase agreement with the warrant holders.

Negatives

The resale of a significant number of shares could potentially depress the market price of Aptevo's common stock.
The company will not receive any proceeds from the resale of these shares by the holders.

Risks

The resale of a large number of shares could depress the market price of the common stock.
Future equity offerings could result in further dilution to investors.
The company's common stock may be at risk for delisting from the Nasdaq Capital Market if it does not maintain compliance with Nasdaq's continued listing requirements, including a minimum bid price of $1.00 per share.
If the common stock is not listed on Nasdaq or another national exchange, the trading of the common stock will be subject to the 'penny stock' rules.

Future Outlook

The company intends to pursue collaborations with other biotechnology and pharmaceutical companies, academia, and non-governmental organizations to advance its product portfolio and expand the ADAPTIR and ADAPTIR-FLEX product pipelines to address areas of unmet medical need.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents, with sixteen new bispecific agents approved by the FDA in the last three years and a total of 125 bispecific drug candidates currently in development.

Related Party Transactions

On April 3, 2025, Aptevo entered into a Purchase Agreement with certain institutional investors, resulting in the issuance of common stock and warrants.

Stakeholder Impact

Existing shareholders may experience dilution if the warrants are exercised and the resale shares are sold.
The market price of Aptevo's common stock could be affected by the resale of a significant number of shares.

Next Steps

The Holders will determine when and how they will dispose of any shares of Common Stock registered under this prospectus for resale.
A special meeting of stockholders will be held on May 14, 2025, to approve the issuance of the Common Warrants.
The company will use commercially reasonable efforts to cause the Resale Registration Statement to become effective by June 2, 2025 (or by July 2, 2025 in case of full review of such registration statement by the SEC).

Key Dates

Date	Description
August 6, 2015	Emergent BioSolutions Inc. announced a plan to separate into two independent publicly traded companies, creating Aptevo.
February 2016	Aptevo was incorporated in Delaware as a wholly owned subsidiary of Emergent.
August 1, 2016	Emergent made a pro rata distribution of Aptevo's Common Stock to Emergent's stockholders.
November 8, 2020	Aptevo's board of directors adopted a rights plan pursuant to the Rights Agreement.
January 2023	Aptevo filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to APVO711.
January 2024	The provisional patent was amended to include new preclinical data and a patent application under the Patent Cooperation Treaty (PCT") pertaining to APVO711.
April 3, 2025	Aptevo entered into a Purchase Agreement with certain institutional investors for the purchase of common stock and warrants.
May 3, 2025	Deadline for Aptevo to file a registration statement on Form S-3 (or other appropriate form, including on Form S-1, if we are not then S-3 eligible) to register the resale of the Resale Shares upon exercise of the Common Warrants (the Resale Registration Statement).
May 12, 2025	Last reported sale price of Aptevo's common stock on the Nasdaq Capital Market was $0.34 per share.
May 13, 2025	Date of the prospectus.
May 14, 2025	Special meeting of stockholders to be held to approve, among other things, the issuance of the Common Warrants.
June 2, 2025	Target date for the Resale Registration Statement to become effective.
July 2, 2025	Extended target date for the Resale Registration Statement to become effective in case of full review by the SEC.
October 31, 2025	The Rights Agreement and the rights granted thereunder will expire.
November 2025 November 2028	Expiration dates for 2023 Common Warrants.

Keywords

resale, common stock, warrants, Aptevo Therapeutics, registration statement, securities, offering

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.